Dracen Pharmaceuticals, Inc.
Dracen Pharmaceuticals is a private pharmaceutical company leveraging immuno-metabolism to create new cancer treatments, with their lead candidate, sirpiglenastat (DRP-104), being a unique glutamine inhibitor.
Funding history
About Dracen Pharmaceuticals, Inc.
How much funding has Dracen Pharmaceuticals, Inc. raised?
Dracen Pharmaceuticals, Inc. has raised $2.3M in total funding. The most recent round was Series A.
Where is Dracen Pharmaceuticals, Inc. headquartered?
Dracen Pharmaceuticals, Inc. is headquartered in San Diego, CA.
What does Dracen Pharmaceuticals, Inc. do?
Dracen Pharmaceuticals is a private pharmaceutical company leveraging immuno-metabolism to create new cancer treatments, with their lead candidate, sirpiglenastat (DRP-104), being a unique glutamine inhibitor.
What makes Dracen Pharmaceuticals, Inc. notable?
Founded by Thomas Estok and Dr. Mohamed Ragab, the cancer-drug developer has raised about $59M from investors including Deerfield Management and i&i Biotech Fund.
Leadership
Related terms
❝ Cite this page
Free to use in articles, research, and reference works. Stable URL, will not change. Data on this page last updated September 3, 2026.
🏷 Embed this badge
Building or fundraising? Add this to your site to show you're listed on SoCal.Startups — the link back helps other founders and investors find you here too.
